<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02589548</url>
  </required_header>
  <id_info>
    <org_study_id>RBLH</org_study_id>
    <nct_id>NCT02589548</nct_id>
  </id_info>
  <brief_title>Brazilian Prospective Hodgkin Lymphoma Registry</brief_title>
  <official_title>Brazilian Prospective Hodgkin Lymphoma Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective registry of Hodgkin Lymphoma (HL) patients in Brazil.

      The purpose of the study is to gather clinical, epidemiologic and outcomes data on the
      treatment of HL, on the basis of records collected by key Brazilian institutions, through a
      centralized web-based registry of clinical data verified by central board of
      hematopathologists.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hodgkin Lymphoma is considered one of the malignancies with highest cure rates. Its prognosis
      improved substantially along the last three decades, as a result of relevant cooperative
      studies carried out in American and European institutions. Around 70-80% of the patients are
      cured with the available chemotherapy regimens.

      However, data about HL in developing countries are scarce. It is well established that
      patients in underprivileged societies present with malignancies in more advanced stages. In
      studies of HL patients treated in Brazil during the 80's, most patients presented with
      advanced disease.

      The creation of registry of patients with HL will provide a more reliable picture of the
      disease in the country, its prevalence in different areas and socioeconomic groups, and
      treatment outcomes. It will also foster the establishment of a network among hospitals in all
      regions of the country, which may serve as a platform for further development of cooperative
      studies engaging the main Brazilian Institutions.

      The data collection allows comparison of data entered into the registry against predefined
      rules for range or consistency with other data fields in the registry. Also, quality
      assurance addresses data validation and data analysis. Standard descriptive analyses will be
      carried out. For a crude association analysis, categorical data will be analysed using the
      chi-square or Fisher's exact test (two-sided). Survival curves will be estimated using the
      Kaplan-Meier method and compare using the log-rank test. Univariate and multivariate Cox
      regression analyses will be conducted to verify the prognostic factors regarding Progression
      free survival and Overall survival, adjusted for relevant prognostic clinical variables and
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event Free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Event free survival</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Hodgkin Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Formalin-fixed tissue for central diagnostic pathology review
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hodgkin Lymphoma patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated HL patients

          -  Clinical data including baseline information on disease localization and laboratory
             parameters at staging, features of treatment adopted and assurance of follow-up
             updating for at least 5 years are requested

          -  Written informed consent

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nelson Spector, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UFRJ</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irene Biasoli</last_name>
    <role>Principal Investigator</role>
    <affiliation>UFRJ</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nelson Spector, MD</last_name>
    <phone>+552139382460</phone>
    <email>spector@ufrj.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irene Biasoli, MD</last_name>
    <phone>+552139382460</phone>
    <email>irene.biasoli@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universidade Federal Do Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>IRENE BIASOLI, MD</last_name>
      <phone>552139382460</phone>
      <email>irene.biasoli@gmail.com</email>
    </contact>
    <investigator>
      <last_name>NELSON CASTRO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MARCIA DELAMAIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>RAFAEL GAIOLLA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BELINDA SIMÃ•ES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CRISTIANA SOLZA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CARLOS CHIATTONE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CAROLINE BONAMIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>NELMA CLEMENTINO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MONICA PRAXEDES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CARLA BOQUIMPANI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>OTAVIO BAIOCCHI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>JAMES FARLEY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>CARMINO DE SOUZA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>KATIA PAGNANO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>October 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2015</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Rio de Janeiro</investigator_affiliation>
    <investigator_full_name>Irene Biasoli</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Hodgkin Lymphoma</keyword>
  <keyword>Hodgkin Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

